To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
De Novo closes $250m life science fund
The Menlo Park, California venture capital firm’s second fund will focus on seed and early stage medical technology and biotechnology opportunities.
